Merck's consumer biz could fetch $10B; X-Chem strikes a deal with Bayer;

@FierceBiotech: Like him or not, Myriad Genetics' Peter Meldrum helped make predictive cancer testing viable. Profile | Follow @FierceBiotech

@JohnCFierce: Who's influential in biopharma? (ICYMI) Report | Follow @JohnCFierce

@DamianFierce: FDA rejects Durect's pitch to market post-operative pain therapy. More | Follow @DamianFierce

@EmilyMFierce: GlaxoSmithKline joins $115M antibiotics development initiative. Story via FierceBiotech Research | Follow @EmilyMFierce

> Merck ($MRK) has made no secret of its inclination to sell off its consumer business, and the segment could go for as much as $10 billion. Story

> Cardiome's ($CRME) long-troubled Brinavess posted some promising results in an investigator-led study on patients with atrial fibrillation. More

> Waltham, MA's X-Chem is licensing an early-stage discovery program to Bayer, part of partnership between the two. Item

Medical Device News

@FierceMedDev: Illumina's Jay Flatley brought sequencing to another level in 2013--the $1000 genome is now a reality. Report | Follow @FierceMedDev

@MarkHFierce: Amedica's IPO is going steadily. Stock at $6.19 as of 10:56 A.M. Moderately higher. Story | Follow @MarkHFierce

@MichaelGFierce: CalTech engineers have created an antibody carrier that could prevent intravaginal HIV infection. Not a vaccine... More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: "Musical hallucinations" give scientists clues about brain function, hearing loss. Article | Follow @EmilyWFierce

> Teleflex triggered a global recall for a tracheal tube that can crease during use. Story

> Illumina and Yuri Milner will back a genomics startup incubator in San Francisco. More

> Blood Purification Technologies gets FDA green light for artificial kidney trials. News

> Miramar Labs raises $10M to market device that eliminates underarm sweat glands. Item

Pharma News

@FiercePharma: More than 2,000 Pradaxa patients are suing Boehringer over severe or fatal bleeding. More | Follow @FiercePharma

@TracyStaton: Our best-read feature every year: The most influential people in biopharma today. Report | Follow @TracyStaton

@EricPFierce: It's 1 thing for an API seller to have poor quality controls, but FDA says it's a real problem to have none. Story | Follow @EricPFierce

@CarlyHFierce: Merck consumer-health deal heats up with $10B-plus bids expected soon. News | Follow @CarlyHFierce

> Antitrust watchdogs come down on Pfizer for Lipitor dealmaking. Story

> Boehringer says it's fighting 2,000 lawsuits over Pradaxa safety. Article

> Merck consumer-health deal heats up with $10B-plus bids expected soon. News

Pharma Manufacturing News

> Congress wants more info about the quality of foreign-made generics. Story

> 2 Hospira plants improve their FDA standing as improvements kick in. Article

> Irish Regeneron plant to produce tax benefits as well as drugs. Story

> Catalent to expand in U.S. and add 230 jobs to its Kansas City operation. News

> The FDA slams a Hong Kong API for the sorry state of its quality controls. Story

> New plants in Middle East are a testament to the region's emerging market status. Item

Vaccines News

> Quadrivalent flu vaccines drive surge in sales at AstraZeneca, GSK and Sanofi. Earnings

> The President's Cancer Panel is pushing for increased use of Merck's and GSK's HPV vaccines. News

> Crowdfunded HIV project draws criticism from scientists. Story

> CDC: Adult vaccination rates are still well below targets. Article

> The U.S. flu season is slowly winding down after hitting some states hard. Story

> Global measles deaths have dropped 78% since 2000. Brief

Suggested Articles

Aptinyx's post-traumatic stress disorder treatment topped placebo on a composite measure of PTSD symptoms, teeing up a pivotal trial next year.

It’s been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech.